Asero R
Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italy.
Clin Exp Allergy. 2005 Jun;35(6):713-6. doi: 10.1111/j.1365-2222.2005.2228.x.
Summary Background In the clinical practice patients with a history of acute urticaria induced by a single non-steroidal anti-inflammatory drug (NSAID) and seeking for safe alternative drugs generally undergo tolerance tests with alternative NSAIDs that have little or no cyclooxygenase-1 (COX-1) enzyme inhibitory activity. This practice does not allow for the detection of single NSAID reactors and may lead to unnecessary avoidance of many potentially useful NSAIDs.
Evaluate aspirin challenge as a means to distinguish single from multiple NSAID intolerance in patients with a clinical history of acute urticaria induced by a single NSAID. Methods One hundred and seventeen otherwise normal subjects with a history of acute urticaria following the ingestion of a single NSAID (pyrazolones (n=58), nimesulide (n=17), propionic acid derivatives (n=13), aryl acetic acid derivatives (n=14), acetaminophen (n=9), piroxicam (n=5), and indometacin (n=1)) underwent single-blind placebo-controlled oral challenges with aspirin. Aspirin-intolerant subjects underwent further tolerance tests drugs exerting little or no inhibitory activity on COX-1 enzyme (including paracetamol, nimesulide, rofecoxib, tramadol, and floctafenine). Results Aspirin induced urticaria in 28/117 (24%) patients. Five out of 28 (18%) aspirin reactors did not tolerate alternative NSAID on subsequent oral challenges. Conclusion In subjects with a history of urticaria induced by a single NSAID (other than aspirin) the diagnostic workup should start with an aspirin challenge in order to detect single/multiple NSAID reactors.
总结背景 在临床实践中,有单次非甾体抗炎药(NSAID)诱发急性荨麻疹病史且寻求安全替代药物的患者,通常会接受对环氧化酶-1(COX-1)酶抑制活性很小或没有抑制活性的替代NSAID的耐受性测试。这种做法无法检测出单一NSAID反应者,可能导致不必要地避免使用许多潜在有用的NSAID。
评估阿司匹林激发试验作为区分单次NSAID不耐受和多次NSAID不耐受的方法,这些患者有单次NSAID诱发急性荨麻疹的临床病史。方法 117名其他方面正常、有单次NSAID(吡唑酮类(n = 58)、尼美舒利(n = 17)、丙酸衍生物(n = 13)、芳基乙酸衍生物(n = 14)、对乙酰氨基酚(n = 9)、吡罗昔康(n = 5)和吲哚美辛(n = 1))摄入后急性荨麻疹病史的受试者,接受了阿司匹林单盲安慰剂对照口服激发试验。阿司匹林不耐受的受试者接受了对COX-1酶抑制活性很小或没有抑制活性的药物(包括对乙酰氨基酚、尼美舒利、罗非昔布、曲马多和氟洛芬那酸)的进一步耐受性测试。结果 阿司匹林在28/117(24%)的患者中诱发了荨麻疹。28名阿司匹林反应者中有5名(18%)在随后的口服激发试验中对替代NSAID不耐受。结论 在有单次NSAID(非阿司匹林)诱发荨麻疹病史的受试者中,诊断检查应从阿司匹林激发试验开始,以检测单次/多次NSAID反应者。